MDGL250516C195000
- 94.00
- 0.000.00%
Madrigal Pharmaceuticals Newsroom
Madrigal Pharmaceuticals Price Target Raised to $460.00/Share From $422.00 by B. Riley Securities
Madrigal Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Madrigal Pharmaceuticals Analyst Ratings
UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating
Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (MDGL) and AptarGroup (ATR)
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Sell Rating, Raises Target Price to $248
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $470
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Madrigal Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating
JMP Securities Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
Cantor Fitzgerald Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating
Evercore Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $392
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Pfizer (PFE) and Madrigal Pharmaceuticals (MDGL)
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $443
Madrigal Pharmaceuticals Analyst Ratings
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
TD Cowen Remains a Buy on Madrigal Pharmaceuticals (MDGL)
Jefferies Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $398
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
TD Cowen Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)